| Adaptive randomization of veliparib–carboplatin treatment in breast cancer HS Rugo, OI Olopade, A DeMichele, C Yau, LJ van’t Veer, MB Buxton, ... New England Journal of Medicine 375 (1), 23-34, 2016 | 591 | 2016 |
| Effect of pembrolizumab plus neoadjuvant chemotherapy on pathologic complete response in women with early-stage breast cancer: an analysis of the ongoing phase 2 adaptively … R Nanda, MC Liu, C Yau, R Shatsky, L Pusztai, A Wallace, AJ Chien, ... JAMA oncology 6 (5), 676-684, 2020 | 545 | 2020 |
| Reproductive risk factors and breast cancer subtypes: a review of the literature KN Anderson, RB Schwab, ME Martinez Breast cancer research and treatment 144, 1-10, 2014 | 488 | 2014 |
| Adaptive randomization of neratinib in early breast cancer JW Park, MC Liu, D Yee, C Yau, LJ van’t Veer, WF Symmans, M Paoloni, ... New England Journal of Medicine 375 (1), 11-22, 2016 | 361 | 2016 |
| HER2 aberrations in cancer: implications for therapy M Yan, BA Parker, R Schwab, R Kurzrock Cancer treatment reviews 40 (6), 770-780, 2014 | 258 | 2014 |
| Residual cancer burden after neoadjuvant chemotherapy and long-term survival outcomes in breast cancer: a multicentre pooled analysis of 5161 patients C Yau, M Osdoit, M van der Noordaa, S Shad, J Wei, D de Croze, ... The Lancet Oncology 23 (1), 149-160, 2022 | 214 | 2022 |
| Real-world data from a molecular tumor board demonstrates improved outcomes with a precision N-of-One strategy S Kato, KH Kim, HJ Lim, A Boichard, M Nikanjam, E Weihe, DJ Kuo, ... Nature communications 11 (1), 4965, 2020 | 205 | 2020 |
| Exploring the landscape of focal amplifications in cancer using AmpliconArchitect V Deshpande, J Luebeck, NPD Nguyen, M Bakhtiari, KM Turner, ... Nature communications 10 (1), 392, 2019 | 204 | 2019 |
| Ovarian cancer stem cells express ROR1, which can be targeted for anti–cancer-stem-cell therapy S Zhang, B Cui, H Lai, G Liu, EM Ghia, GF Widhopf, Z Zhang, CCN Wu, ... Proceedings of the National Academy of Sciences 111 (48), 17266-17271, 2014 | 197 | 2014 |
| A role for the caveolin scaffolding domain in mediating the membrane attachment of caveolin-1: the caveolin scaffolding domain is both necessary and sufficient for membrane … A Schlegel, RB Schwab, PE Scherer, MP Lisanti Journal of Biological Chemistry 274 (32), 22660-22667, 1999 | 196 | 1999 |
| Molecular tumor board: the University of California San Diego Moores cancer center experience M Schwaederle, BA Parker, RB Schwab, PT Fanta, SG Boles, GA Daniels, ... The oncologist 19 (6), 631-636, 2014 | 187 | 2014 |
| Precision oncology: The UC San Diego moores cancer center predict experience M Schwaederle, BA Parker, RB Schwab, GA Daniels, DE Piccioni, ... Molecular cancer therapeutics 15 (4), 743-752, 2016 | 177 | 2016 |
| Gene-target recognition among members of the myc superfamily and implications for oncogenesis RC O'Hagan, N Schreiber-Agus, K Chen, G David, JA Engelman, ... Nature genetics 24 (2), 113-119, 2000 | 175 | 2000 |
| Detection rate of actionable mutations in diverse cancers using a biopsy-free (blood) circulating tumor cell DNA assay M Schwaederle, H Husain, PT Fanta, DE Piccioni, S Kesari, RB Schwab, ... Oncotarget 7 (9), 9707, 2016 | 163 | 2016 |
| Durvalumab with olaparib and paclitaxel for high-risk HER2-negative stage II/III breast cancer: Results from the adaptively randomized I-SPY2 trial L Pusztai, C Yau, DM Wolf, HS Han, L Du, AM Wallace, E String-Reasor, ... Cancer cell 39 (7), 989-998. e5, 2021 | 159 | 2021 |
| Nrf2 responses and the therapeutic selectivity of electrophilic compounds in chronic lymphocytic leukemia RP Wu, T Hayashi, HB Cottam, G Jin, S Yao, CCN Wu, MD Rosenbach, ... Proceedings of the National Academy of Sciences 107 (16), 7479-7484, 2010 | 155 | 2010 |
| Depression as a predictor of adherence to adjuvant endocrine therapy (AET) in women with breast cancer: a systematic review and meta-analysis BT Mausbach, RB Schwab, SA Irwin Breast cancer research and treatment 152, 239-246, 2015 | 154 | 2015 |
| Human xeno-autoantibodies against a non-human sialic acid serve as novel serum biomarkers and immunotherapeutics in cancer V Padler-Karavani, N Hurtado-Ziola, M Pu, H Yu, S Huang, S Muthana, ... Cancer research 71 (9), 3352-3363, 2011 | 153 | 2011 |
| Use of liquid biopsies in clinical oncology: pilot experience in 168 patients M Schwaederle, H Husain, PT Fanta, DE Piccioni, S Kesari, RB Schwab, ... Clinical cancer research 22 (22), 5497-5505, 2016 | 146 | 2016 |
| Association of event-free and distant recurrence–free survival with individual-level pathologic complete response in neoadjuvant treatment of stages 2 and 3 breast cancer … D Yee, AM DeMichele, C Yau, C Isaacs, WF Symmans, KS Albain, ... JAMA oncology 6 (9), 1355-1362, 2020 | 145 | 2020 |
